Profile

Biography

Susan is a Senior Research Fellow based in the Team for Economic Evaluation and Health Technology Assessment. She joined the Centre for Health Economics in 2002 and holds a BSc in Economics, an MSc in Health Economics and a PhD on ‘Dealing with uncertainty in the economic evaluation of health care technologies’.  In 2008 Susan became a Research Council UK Academic Fellow in Health Economics and Public Health.  She also helped to develop a short course on the use of regression analysis for health economic evaluation.  Susan currently serves as a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee.

Susan has contributed to numerous technology appraisals for NICE in her role as a member of one of the independent academic groups contracted to conduct assessments and evidence reviews for NICE.  In addition, Susan has worked on economic evaluations in the fields of cardiovascular disease, HIV/AIDS, cancer and mental health.  Her research interests include the use of decision-analytic models in cost-effectiveness analysis and the use of evidence synthesis techniques and value of information analysis.  Susan is currently researching the application of methods for economic evaluation in the field of public health

Research

Overview

• the use of decision-analytic models in cost-effectiveness analysis
• the use of evidence synthesis techniques and value of information analysis
• economic evaluations in the fields of cardiovascular disease, HIV/AIDS, cancer and mental health
• the application of methods for economic evaluation in the field of public health

Research group(s)

• Economic evaluation of health technologies
  

Publications

Full publications list

Downloads

• The technical report of the methods used in "Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study" is available to download here Cost Effectiveness of clinically appropriate decisions (PDF , 286kb)

2012

• Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin S, Sun H, Holodniy M, Brown ST, Kyriakides TC, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. Effect of treatment interruption and intensification of antiretroviral therapy on health related quality of life in patients with advanced HIV: a randomized, controlled trial. Medical Decision Making 2012;32(1):70-82. Download from sagepub

2011

• Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin S, Nosyk B, Holodniy M, Brown ST, Sculpher M, Anis AH, Owens DK. Determinants of the cost of health services used by veterans with HIV. Medical Care 2011;49(9):848-56. Download from pubmed
• Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer 2011;Nov 47(17):2517-30. Download from Sciencedirect
• Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman E, Youn J. Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies. Centre for Health Economics, University of York; CHE Research Paper 69 (PDF , 1,860kb) 2011.
• Griffin S, Claxton K. Analysing uncertainty in cost-effectiveness for decision making. In: Glied S, Smith PC, editors. Oxford Handbook of Health Economics. Oxford: Oxford University Press; 2011.
• Griffin S, Claxton K, Palmer S, Sculpher M. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Economics 2011;20:212-24.  
• Walker S, Burch J, McKenna C, Wright K, Griffin S, Woolacott N. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: Health Technology Assessment 2011;15:Suppl.1:13-21.

2010

• Griffin S, Claxton K, Welton N. Exploring the research decision space: the expected value of information for sequential research designs. Medical Decision Making 2010;30:155-62. Download from Sage journals
• Griffin S, Rice N, Sculpher M. Economic evaluation of public health interventions. In: Killoran A, Kelly M, editors. Evidence-based public health: effectiveness and efficiency. Oxford: Oxford University Press; 2010.
• Paulden M, Rodgers M, Griffin S, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M. Alitretinoin for the treatment of severe chronic hand eczema. Health Technology Assessment 2010;14(s1):39-46. Download from NIHR
• Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Wollacott N, Sculpher M. Alitretinoin for Severe Chronic Hand Eczema: A NICE Single Technology Appraisal. Pharmacoeconomics 2010;28(5):351-62. Download from Pubmed

2009

• Griffin S, Dunn G, Palmer S, Macfarlane S, Brent S, Dyker A, et al. The use of paclitaxel in the management of early stage breast cancer. Health Technology Assessment: 2009;13(s1):15-22.
• Griffin S, Walker S, Sculpher M, et al. Cetuximab plus radiotherapy for the treatment of locally advance squamous cell carcinmoa of the head and neck. Health Technology Assessment: 2009;13(s1):49-54. Download from HTA
• McDaid C, Duree KH, Griffin SC, Weatherly HLA, Stradling JR, Davies RJO, Sculpher MJ, Westwood ME. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome.Sleep Medicine Reviews 2009;13(6):427-36. Download from Sleep Medicine
• McDaid C, Griffin S, Weatherly H, Duree KH, Burgt van der M, Hout van S, Akers J, Davies RJO, Sculpher M, Westwood M. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. Health Technology Assessment. 2009; 13(4) pp1-142.
• Weatherly HLA, Griffin S, McDaid C, Duree KH, Davies RJO, Stradling JR, Sculpher MJ et al. An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. International Journal of Technology Assessment in Health Care. 2009;25(01):26-34.

2008

• Bansback N, Sun H, Guh D, Li X, Nosyk B, Griffin S, et al. The impact of using a recall period on the measurement of health utilities for acute events. Health Economics. 2008;17(12):1413-9.
• Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. Journal of Health Services Research and Policy. 2008;13:23-30. Download from RSM journals
• Griffin S, Weatherly H, Richardson G, Drummond M. Methodological issues in undertaking independant cost-effectiveness analysis for NICE: the case of therapies for ADHD. The European Journal of Health Economics. 2008;9(2):137-45
• Ryan M, Griffin S, Chitah B, Walker SA, Mulenga V, Kalolo D, Hawkins N, Sculpher MJ, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. Aids. 2008;22:749-57.

2007

• Griffin SC, Barber JA, Manca A, Sculpher M, Thompson SG, Buxton MJ, et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina. British Medical Journal. 2007;334(7594):624.
• Griffin S, Claxton K, Hawkins N, Sculpher M. Decision models need to be fit for purpose for decision making: response to Caro et al. Value in Health. 2007;10(4):319. Download from Wiley Inter Science
• McDaid C, Griffin S, Weatherly H. The continuous positive airway pressure for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis: Assessment report for the National Institute for Health and Clinical Excellance; September 2007. Download from NICE

2006

• Griffin S, Claxton K, Hawkins N, Sculpher MJ (2006). Probabilistic analysis and computationally expensive models: necessary and required? Value in Health 2006:9;244-252.
• Griffin S, Bojke L, Main C, Palmer S. Incorporating direct and indirect evidence using bayesian methods: an applied case study in ovarian cancer. Value in Health. 2006;9(2):123-31.
• King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Winchester, England: Health Technology Assessment 2006:10(23);iii+146.
• Main C, Ginnelly L, Griffin S, Norman G, Barbieri M, Mather L, et al. A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update). Health Technology Assessment 2006:10(9).

2005

• Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, et al. A pilot study of value of information analysis to support research recommendations for the National Institute for Health and Clinical Excellence. Centre for Health Economics, University of York; CHE Research Paper 4 (PDF , 1,149kb) , 2005.

2004

• Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R. Clopidogrel used in combination with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technology Assessment 2004;8(40):1-176.
• Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technology Assessment 2004;8(38):1-210.

Presentations

• Griffin S. Dealing with uncertainty in decison models (PDF , 189kb) Health Economics Unit, Birmingham University. December 2010.
• Griffin S.  MRC, London, March 2010. Presentation titled, Cost-effectiveness in OPTIMA.
• Griffin S. Panel session Enhancing the case for research funding with economic evaluation (PDF , 399kb)  HTAi, Dublin, Ireland, June 2010.
• Griffin S. Seminar titled, Adapting methods for the cost-effectiveness analysis of healthcare interventions (PDF , 378kb) to incorporate concerns for inequality in the distribution of health. Department of Health, London, UK, July 2010. 
• Griffin S. Panel presentation, Reflecting equity considerations in economic evaluation. Workshop in methods of economic evaluation in public health research, University of York, July 2010.
• Griffin S. Seminar titled, Enhancing the case for research funding with economic evaluation (PDF , 399kb) Erasmus University of Rotterdam, Netherlands August 2010. 
• Griffin S.  Analysing clinical trial data to inform inputs to decision models. Poster presentation at SMDM meeting in Hollywood, LA, October 2009.
• Griffin S. Dangerous omissions: the consequences of ignoring decision uncertainty  PATH. McMaster University, Toronto June 2009. Dangerous Omissions: The Consequences of Ignoring Decision Uncertainty PATH (PDF , 343kb)
• Griffin S. Dangerous omissions: the consequences of ignoring decision uncertainty  THETA. University of Toronto June 2009. Dangerous Omissions: The Consequences of Ignoring Decision Uncertainty THETA (PDF , 330kb)
• Griffin S. What is the balance between certainty and uncertainty?  Faculty of Public Health Annual Conference. Scarborough June 2009. What is the balance between certainty and uncertainty (PDF , 170kb)
• Griffin S. Interpreting the expected value of perfect information about parameters. Poster presentation at annual SMDM meeting in Pittsburgh, October 2007. Interpreting the expected value of perfect information about parameters (PDF , 202kb) .
• Griffin S. An application of a bivariate random effects meta-analysis in a cost-effectiveness analysis of treatment for sleep apnoea. Poster presentation at annual SMDM meeting in Pittsburgh, October 2007. An application of a bivariate random effects (PDF , 141kb) .
• Griffin S. Dangerous omissions: the consequences of ignoring decision uncertainty. Poster presentation at annual SMDM meeting in Boston, October 2006. Dangerous Omissions SMDM (PDF , 280kb)
• Incorporating direct and indirect evidence using Bayesian methods (PDF , 191kb)
• Griffin S. Cost-effectiveness of second-line chemotherapies for ovarian cancer. Presentation at 5th World Congress of iHEA in Barcelona 10-13th July 2005. Griffin S. Combining multiply imputed datasets to produce cost-effectiveness acceptability curves comparing three or more treatment options. Presented at the HESG meeting in Paris, January 2004.
• Griffin S. Probabilistic analysis and computationally expensive models: necessary and required? Presented at the SMDM meeting in Atlanta, October 2004.

Teaching

Other teaching

Centre for Health Economics

• Regression Methods for Health Economic Evaluation - Course tutor
• Advanced Modelling Methods for Health Economic Evaluation - Course tutor
• York Expert Workshops in the Socio Economic Evaluation of Medicines - Course tutor

 Distance learning

• The Postgraduate Diploma in Health Economics for Health Care Professionals  - Module leader for Advanced topics in Economic Evaluation

External activities

Memberships

• National Institute for Health and Clinical Excellence - member of the Technology Appraisal Committee
• Health Economists’ Study Group - member
• Society for Medical Decision Making - member
• International Health Economics Association  - member